Osta Biotechnologies Inc.
NEX BOARD : OBI

Osta Biotechnologies Inc.

August 08, 2012 11:02 ET

Osta Announces Change of Auditors

MONTREAL, QUEBEC--(Marketwire - Aug. 8, 2012) -

THE ISSUE OF THIS PRESS RELEASE IS LIMITED TO CANADA ONLY. THIS PRESS RELEASE SHOULD NOT BE ISSUED IN THE UNITED STATES THROUGH U.S. NEWS WIRE AGENCIES.

Osta Biotechnologies Inc. (NEX:OBI) advises that MNP S.E.N.C.R.L. have resigned as auditors of the Company. Accordingly, the Company, on behalf of the Audit Committee and the Board of Directors, has appointed Nexia Friedman LLP Chartered Accountants as successor auditors to MNP effective August 6, 2012.

There have been no reservations contained in the auditor's reports rendered by MNP for the two most recent fiscal years and, in the opinion of the Company, no reportable events within the meaning of National Instrument 51-102 have occurred prior to the date hereof. The Company will file the required Notice of Change of Auditor reporting package in accordance with National Instrument 51-102. The resignation by MNP was not the result of any disagreement between the Company and MNP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.

About Osta Biotechnologies Inc.

Osta is a biopharmaceutical company listed on the NEX board of the TSX Venture Exchange currently focusing on developing therapeutics for Cancer and Alzheimer's disease.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Osta Biotechnologies Inc.
    Dr. Ajay Gupta
    Chairman & CEO
    (514) 626-9519

    Mr. William Waks
    CFO and VP Finance
    (514) 817-3380